Immunotherapies for Prostate Cancer

Publication
Article
Special ReportsImmunotherapy (Issue 4)
Volume 4
Issue 1

William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses immunotherapies for the treatment of patients with prostate cancer.

<<<

Back to the Immunotherapy Special Report

Articles in this issue
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Question
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Question
Programs Prepare for Immuno-Oncology in Clinical Setting
Programs Prepare for Immuno-Oncology in Clinical Setting
Right Patient for Immunotherapy in NSCLC Explored
Right Patient for Immunotherapy in NSCLC Explored
Weight May Affect Toxicity of Immunotherapies
Weight May Affect Toxicity of Immunotherapies
Adverse Events Associated With Immunotherapy in Lung Cancer
Adverse Events Associated With Immunotherapy in Lung Cancer
Immunotherapy Potential Option in Mesothelioma Treatment
Immunotherapy Potential Option in Mesothelioma Treatment
Potential Immunotherapies for Head and Neck Cancers
Potential Immunotherapies for Head and Neck Cancers
Immunotherapies for Prostate Cancer
Immunotherapies for Prostate Cancer
Recent Videos
Related Content
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

Jordyn Sava
November 21st 2024
Article

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Jordyn Sava
November 18th 2024
Article

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

Jordyn Sava
November 15th 2024
Article

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Read More